Section Arrow
NTLA.NASDAQ
- Intellia Therapeutics
Quotes are at least 15-min delayed:2026/02/09 06:35 EST
Pre Market
Last
 12.27
-0.01 (-0.08%)
Bid
12.05
Ask
12.3
High 12.5 
Low 12.2 
Volume 6.89K 
Regular Hours (Closed)
Last
 12.28
+1.19 (+10.73%)
Day High 
12.33 
Prev. Close
11.09 
1-M High
17.09 
Volume 
4.61M 
Bid
12.05
Ask
12.3
Day Low
11.32 
Open
11.32 
1-M Low
9.31 
Market Cap 
1.43B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 13.38 
20-SMA 12.85 
50-SMA 10.64 
52-W High 28.25 
52-W Low 5.9 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.25/1.01
Enterprise Value
1.62B
Balance Sheet
Book Value Per Share
6.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
57.88M
Operating Revenue Per Share
0.46
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc1.84-0.21-10.24%-- 
Pre Market 1.72 -0.12 -6.52%
RXRXRecursion Pharmaceuticals3.98+0.42+11.80%-- 
Pre Market 4.01 +0.03 +0.75%
FOLDAmicus Therapeutics14.3+0.02+0.14%-- 
Pre Market 14.35 +0.05 +0.35%
ARWRArrowhead Pharmaceuticals64.52-0.12-0.19%-- 
Pre Market 64.19 -0.33 -0.51%
ROIVRoivant Sciences Ltd25.82+4.68+22.14%1.95PE
Pre Market 25.48 -0.34 -1.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.